Fig. 5From: Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trialDifferences in 99mTc-NM-02 uptake in primary lesions (A) and metastases (B) among three newly diagnosed patients with HER2-positive breast cancer and four previously treated patients with HER2-positive breast cancer after multiple cycles of HER2-targeted therapyBack to article page